



#6 (PB)
8/25/2

RECEIVED
AUG 19 2002
PATENT
TECH CENTER 1600/2900

ATTORNEY DOCKET NO.: 0562901

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

THOMAS et al.

10/069019

Appln. No.: ~~10/069,091~~

Filed: February 21, 2002

FOR: IMIDAZO[1,2-A]PYRIDINE AND
PYRAZOLO[2,3-A]PYRIDINE
DERIVATIVES

)
)
)
)
) Group Art Unit: 1624
)
) Examiner: Unassigned
)
)
)

Commissioner of Patents
Washington, D.C. 20231

Date: August 16, 2002

Sir:

INFORMATION DISCLOSURE STATEMENT

Citation of Related U.S. Patent Applications

The Examiner's attention is directed to the following related co-pending U.S. patent applications. The Table below lists the co-pending U.S. applications which are national stage applications of corresponding PCT published applications, the publications numbers of which are also listed. The corresponding published PCT applications are listed on the attached Form PTO-1449 and copies of the published PCT applications are enclosed in the attached reference collection. The U.S. applications are essentially identical to the corresponding published PCT applications. Therefore, in order to reduce the bulk of this filing and the resulting U.S. Patent Office file, copies of only the corresponding published PCT applications are enclosed. If the Examiner also requires copies of the U.S. applications, it is requested that he telephone the undersigned.

Examiner's Initials	Inventor	U.S. Serial No.	U.S. Filing Date	PCT Publication No.	PCT Publication Date
	Breault et al.	09/763,705	02/26/01	WO 00/12485	Mar 9, 2000
	Breault et al.	09/763,681	02/26/01	WO 00/12486	March 9, 2000
	Bradbury et al.	09/868,602	06/20/01	WO 00/39101	July 6, 2000
	Breault et al.	09/914,788	09/05/01	WO 00/53595	Sept. 14, 2000
	Breault	09/958,077	10/04/01	WO 00/59892	Oct. 12, 2000
	Thomas et al.	10/069,019	02/21/02	WO 01/14375	Mar. 1, 2001

PLEASE DO NOT PRINT the above information regarding the U.S. patent applications on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

Citation of Documents

Attached is a Form PTO-1449 listing the enclosed documents.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted,

prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.

Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 056291-5011 and proceed to consider this IDS.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** -in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP

By: 

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

Date: August 16, 2002
Morgan Lewis & Bockius LLP
Customer No. **009629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk